

Michael H Davidson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2079960/publications.pdf>

Version: 2024-02-01

111
papers

6,168
citations

76326

40
h-index

69250

77
g-index

112
all docs

112
docs citations

112
times ranked

6406
citing authors

#	ARTICLE	IF	CITATIONS
1	Omega-3 fatty acids and coronary heart disease risk: Clinical and mechanistic perspectives. <i>Atherosclerosis</i> , 2008, 197, 12-24.	0.8	470
2	Efficacy and tolerability of adding prescription Omega-3 fatty acids 4 g/d to Simvastatin 40 mg/d in hypertriglyceridemic patients: An 8-week, randomized, double-blind, placebo-controlled study. <i>Clinical Therapeutics</i> , 2007, 29, 1354-1367.	2.5	371
3	Final Conclusions and Recommendations of the National Lipid Association Statin Safety Assessment Task Force. <i>American Journal of Cardiology</i> , 2006, 97, S89-S94.	1.6	370
4	Safety Considerations with Fibrate Therapy. <i>American Journal of Cardiology</i> , 2007, 99, S3-S18.	1.6	332
5	Position paper Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel. <i>Archives of Medical Science</i> , 2015, 1, 1-23.	0.9	311
6	Colesevelam Hydrochloride (Cholestagel). <i>Archives of Internal Medicine</i> , 1999, 159, 1893.	3.8	269
7	Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists. <i>Journal of Clinical Lipidology</i> , 2011, 5, 338-367.	1.5	235
8	Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial. <i>Journal of Clinical Lipidology</i> , 2014, 8, 94-106.	1.5	198
9	Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. <i>Expert Review of Cardiovascular Therapy</i> , 2008, 6, 391-409.	1.5	197
10	Genetics and Causality of Triglyceride-Rich Lipoproteins in Atherosclerotic Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2525-2540.	2.8	192
11	A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: The ECLIPSE (Epanova® compared to Lovaza® in a Tj ETQ) 1 0.784314 rgBT	1.0	143
12	Safety of Aggressive Lipid Management. <i>Journal of the American College of Cardiology</i> , 2007, 49, 1753-1762.	2.8	144
13	Consensus Panel Recommendation for Incorporating Lipoprotein-Associated Phospholipase A2 Testing into Cardiovascular Disease Risk Assessment Guidelines. <i>American Journal of Cardiology</i> , 2008, 101, S51-S57.	1.6	133
14	ACAT Inhibition and Progression of Carotid Atherosclerosis in Patients With Familial Hypercholesterolemia. <i>JAMA - Journal of the American Medical Association</i> , 2009, 301, 1131.	7.4	128
15	Increased High-Density Lipoprotein Cholesterol Predicts the Pioglitazone-Mediated Reduction of Carotid Intima-Media Thickness Progression in Patients With Type 2 Diabetes Mellitus. <i>Circulation</i> , 2008, 117, 2123-2130.	1.6	118
16	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm – 2020 Executive Summary. <i>Endocrine Practice</i> , 2020, 26, 1196-1224.	2.1	117
17	Statin Safety: An Assessment Using an Administrative Claims Database. <i>American Journal of Cardiology</i> , 2006, 97, S61-S68.	1.6	111
18	Statin Safety: An Appraisal from the Adverse Event Reporting System. <i>American Journal of Cardiology</i> , 2006, 97, S32-S43.	1.6	98

#	ARTICLE	IF	CITATIONS
19	A Highly Bioavailable Omega-3 Free Fatty Acid Formulation Improves the Cardiovascular Risk Profile in High-Risk, Statin-Treated Patients With Residual Hypertriglyceridemia (the ESPRIT Trial). <i>Clinical Therapeutics</i> , 2013, 35, 1400-1411.e3.	2.5	94
20	Comparative effects of lipid-lowering therapies. <i>Progress in Cardiovascular Diseases</i> , 2004, 47, 73-104.	3.1	92
21	Omega-3 fatty acids. <i>Current Opinion in Lipidology</i> , 2013, 24, 467-474.	2.7	83
22	Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions. <i>Expert Opinion on Drug Safety</i> , 2006, 5, 145-156.	2.4	78
23	ω-6 Polyunsaturated Fatty Acids and Cardiometabolic Health: Current Evidence, Controversies, and Research Gaps. <i>Advances in Nutrition</i> , 2018, 9, 688-700.	6.4	73
24	Omega-3 fatty acid concentrates in the treatment of moderate hypertriglyceridemia. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 1237-1248.	1.8	72
25	Apolipoprotein Measurements: Is More Widespread Use Clinically Indicated?. <i>Clinical Cardiology</i> , 2009, 32, 482-486.	1.8	72
26	Rosuvastatin safety: lessons from the FDA review and post-approval surveillance. <i>Expert Opinion on Drug Safety</i> , 2004, 3, 547-557.	2.4	71
27	Steady-state bioavailability of prescription omega-3 on a low-fat diet is significantly improved with a free fatty acid formulation compared with an ethyl ester formulation: the ECLIPSE II study. <i>Vascular Health and Risk Management</i> , 2013, 9, 563.	2.3	71
28	Niacin Use and Cutaneous Flushing: Mechanisms and Strategies for Prevention. <i>American Journal of Cardiology</i> , 2008, 101, S14-S19.	1.6	70
29	Lipid measurements in the management of cardiovascular diseases: Practical recommendations a scientific statement from the national lipid association writing group. <i>Journal of Clinical Lipidology</i> , 2021, 15, 629-648.	1.5	69
30	Reducing Residual Risk for Patients on Statin Therapy: The Potential Role of Combination Therapy. <i>American Journal of Cardiology</i> , 2005, 96, 3-13.	1.6	68
31	High-Density Lipoprotein Metabolism: Potential Therapeutic Targets. <i>American Journal of Cardiology</i> , 2007, 100, S32-S40.	1.6	65
32	Cardiovascular Effects of Glucagonlike peptide-1 Agonists. <i>American Journal of Cardiology</i> , 2011, 108, 33B-41B.	1.6	65
33	Lipid Responses to a Dietary Docosahexaenoic Acid Supplement in Men and Women with Below Average Levels of High Density Lipoprotein Cholesterol. <i>Journal of the American College of Nutrition</i> , 2005, 24, 189-199.	1.8	62
34	Effects of Fenofibric Acid on Carotid Intima-Media Thickness in Patients With Mixed Dyslipidemia on Atorvastatin Therapy. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 1298-1306.	2.4	59
35	Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib. <i>Journal of Lipid Research</i> , 2013, 54, 467-472.	4.2	52
36	Striated Muscle Safety of Ezetimibe/Simvastatin (Vytorin). <i>American Journal of Cardiology</i> , 2006, 97, 223-228.	1.6	46

#	ARTICLE	IF	CITATIONS
37	Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial. <i>Lipids in Health and Disease</i> , 2015, 14, 98.	3.0	46
38	The burden of familial chylomicronemia syndrome: interim results from the IN-FOCUS study. <i>Expert Review of Cardiovascular Therapy</i> , 2017, 15, 415-423.	1.5	44
39	The burden of familial chylomicronemia syndrome: Results from the global IN-FOCUS study. <i>Journal of Clinical Lipidology</i> , 2018, 12, 898-907.e2.	1.5	44
40	Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: A 12-week, multicenter, double-blind, randomized, parallel-group study. <i>Clinical Therapeutics</i> , 2009, 31, 2824-2838.	2.5	43
41	Overcoming toxicity and side-effects of lipid-lowering therapies. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2014, 28, 439-452.	4.7	41
42	The use of colestevam hydrochloride in the treatment of dyslipidemia: a review. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 2569-2578.	1.8	34
43	Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting. <i>Journal of Clinical Lipidology</i> , 2013, 7, 102-108.	1.5	34
44	Global Risk Management in Patients with Type 2 Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2007, 99, 41-50.	1.6	33
45	Differences between clinical trial efficacy and real-world effectiveness. <i>American Journal of Managed Care</i> , 2006, 12, S405-11.	1.1	33
46	Novel developments in omega-3 fatty acid-based strategies. <i>Current Opinion in Lipidology</i> , 2011, 22, 437-444.	2.7	29
47	Cardiovascular Risk Factors in a Patient with Diabetes Mellitus and Coronary Artery Disease: Therapeutic Approaches to Improve Outcomes: Perspectives of a Preventive Cardiologist. <i>American Journal of Cardiology</i> , 2012, 110, 43B-49B.	1.6	29
48	Management of Dyslipidemia in Patients with Complicated Metabolic Syndrome. <i>American Journal of Cardiology</i> , 2005, 96, 22-25.	1.6	27
49	Combination therapy in the management of complex dyslipidemias. <i>Current Opinion in Lipidology</i> , 2004, 15, 423-431.	2.7	25
50	A Review of the Current Status of the Management of Mixed Dyslipidemia Associated with Diabetes Mellitus and Metabolic Syndrome. <i>American Journal of Cardiology</i> , 2008, 102, 19L-27L.	1.6	24
51	Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial. <i>Journal of Clinical Lipidology</i> , 2018, 12, 321-330.	1.5	24
52	Novel Targets that Affect High-Density Lipoprotein Metabolism: The Next Frontier. <i>American Journal of Cardiology</i> , 2009, 104, 52E-57E.	1.6	23
53	Comparison of the Lipid-Lowering Effects of Pitavastatin 4 mg Versus Pravastatin 40 mg in Adults With Primary Hyperlipidemia or Mixed (Combined) Dyslipidemia: A Phase IV, Prospective, US, Multicenter, Randomized, Double-blind, Superiority Trial. <i>Clinical Therapeutics</i> , 2014, 36, 1211-1222.	2.5	22
54	The effect of omega-3 carboxylic acids on apolipoprotein CIII-containing lipoproteins in severe hypertriglyceridemia. <i>Journal of Clinical Lipidology</i> , 2016, 10, 1442-1451.e4.	1.5	22

#	ARTICLE	IF	CITATIONS
55	The Risk of Hepatotoxicity, New Onset Diabetes and Rhabdomyolysis in the Era of High-Intensity Statin Therapy: Does Statin Type Matter?. <i>Progress in Cardiovascular Diseases</i> , 2016, 59, 145-152.	3.1	21
56	Is LDL-C Passed Its Prime?. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 1582-1583.	2.4	19
57	Predictors of anterior and posterior wall carotid intima media thickness progression in men and women at moderate risk of coronary heart disease. <i>Journal of Clinical Lipidology</i> , 2011, 5, 141-151.	1.5	18
58	The Efficacy of Colesevelam HCl in the Treatment of Heterozygous Familial Hypercholesterolemia in Pediatric and Adult Patients. <i>Clinical Therapeutics</i> , 2013, 35, 1247-1252.	2.5	18
59	Management of lipoprotein X and its complications in a patient with primary sclerosing cholangitis. <i>Clinical Lipidology</i> , 2015, 10, 305-312.	0.4	18
60	Underappreciated Opportunities for High-Density Lipoprotein Particles in Risk Stratification and Potential Targets of Therapy. <i>Cardiovascular Drugs and Therapy</i> , 2015, 29, 41-50.	2.6	16
61	The future of n-3 polyunsaturated fatty acid therapy. <i>Current Opinion in Lipidology</i> , 2016, 27, 570-578.	2.7	16
62	Study Design, Rationale, and Baseline Characteristics: Evaluation of Fenofibric Acid on Carotid Intima-Media Thickness in Patients with Type IIb Dyslipidemia with Residual Risk in Addition to Atorvastatin Therapy (FIRST) Trial. <i>Cardiovascular Drugs and Therapy</i> , 2012, 26, 349-358.	2.6	14
63	Triglyceride-rich lipoprotein cholesterol (TRL-C): the ugly stepsister of LDL-C. <i>European Heart Journal</i> , 2018, 39, 620-622.	2.2	13
64	Systemic Bioavailability and Dose Proportionality of Omega-3 Administered in Free Fatty Acid Form Compared With Ethyl Ester Form: Results of a Phase 1 Study in Healthy Volunteers. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2017, 42, 815-825.	1.6	12
65	Hypercholesterolemia Treatment Patterns and Low-Density Lipoprotein Cholesterol Monitoring in Patients with a Diagnosis of Atherosclerosis in Clinical Practice. <i>American Journal of Medicine</i> , 2009, 122, S51-S59.	1.5	11
66	Potential Impact of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Pathophysiology in Type 2 Diabetes Mellitus. <i>Postgraduate Medicine</i> , 2014, 126, 56-65.	2.0	11
67	Therapeutic ultrasound: Increased HDL-Cholesterol following infusions of acoustic microspheres and apolipoprotein A-I plasmids. <i>Atherosclerosis</i> , 2015, 241, 92-99.	0.8	11
68	Role of Ezetimibe in Lipid-Lowering and Cardiovascular Disease Prevention. <i>Current Atherosclerosis Reports</i> , 2015, 17, 72.	4.8	11
69	Considerations in the Treatment of Dyslipidemia Associated With Chronic Kidney Failure and Renal Transplantation. <i>Preventive Cardiology</i> , 2005, 8, 244-249.	1.1	10
70	Focusing on High-Density Lipoprotein for Coronary Heart Disease Risk Reduction. <i>Cardiology Clinics</i> , 2011, 29, 105-122.	2.2	10
71	Pioglitazone Versus Glimepiride on Coronary Artery Calcium Progression in Patients With Type 2 Diabetes Mellitus. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010, 30, 1873-1876.	2.4	9
72	Development and Content Validity of the Statin Experience Assessment Questionnaire (SEAQ)®. <i>Patient</i> , 2017, 10, 321-334.	2.7	9

#	ARTICLE	IF	CITATIONS
73	Rosuvastatin in Elderly Patients. <i>Drugs and Aging</i> , 2007, 24, 933-944.	2.7	7
74	Addition of omega-3 carboxylic acids to statin therapy in patients with persistent hypertriglyceridemia. <i>Expert Review of Cardiovascular Therapy</i> , 2014, 12, 1045-1054.	1.5	7
75	Is ezetimibe/simvastatin no better than simvastatin alone? Lessons learned and clinical implications. <i>Cleveland Clinic Journal of Medicine</i> , 2008, 75, 479-496.	1.3	7
76	Comparing remnant lipoprotein cholesterol measurement methods to evaluate efficacy of ezetimibe/statin vs statin therapy. <i>Journal of Clinical Lipidology</i> , 2019, 13, 997-1007.e8.	1.5	6
77	How I treat statin-associated side effects in an outpatient setting. <i>Future Cardiology</i> , 2021, 17, 1249-1260.	1.2	6
78	Biologic therapies for dyslipidemia. <i>Current Atherosclerosis Reports</i> , 2004, 6, 69-72.	4.8	5
79	Retrospective Comparison of the Effectiveness of a Fenofibrate 145mg Formulation Compared with the Standard 160mg Tablet. <i>Clinical Drug Investigation</i> , 2008, 28, 615-623.	2.2	5
80	Interrupting bile-acid handling and lipid and glucose control: Effects of colestevlam on glucose levels. <i>Journal of Clinical Lipidology</i> , 2008, 2, S29-S33.	1.5	5
81	Introduction. <i>American Journal of Cardiology</i> , 2011, 108, 1B-2B.	1.6	5
82	Evolution of Omega-3 Fatty Acid Therapy and Current and Future Role in the Management of Dyslipidemia. <i>Cardiology Clinics</i> , 2018, 36, 277-285.	2.2	5
83	How Genomics Is Personalizing the Management of Dyslipidemia and Cardiovascular Disease Prevention. <i>Current Cardiology Reports</i> , 2018, 20, 138.	2.9	5
84	The Effect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition on Sterol Absorption Markers in a Cohort of Real-World Patients. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2019, 24, 54-61.	2.0	5
85	Targeting the cytoskeleton and extracellular matrix in cardiovascular disease drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2022, 17, 443-460.	5.0	5
86	New Concepts in Dyslipidemia in the Metabolic Syndrome and Diabetes. <i>Metabolic Syndrome and Related Disorders</i> , 2006, 4, 299-314.	1.3	4
87	Targeting High-Density Lipoprotein Cholesterol in the Management of Cardiovascular Disease. <i>The American Heart Hospital Journal</i> , 2007, 5, 210-216.	0.2	4
88	Large high-density lipoprotein particle number is independently associated with microvascular function in patients with well-controlled low-density lipoprotein concentration: A vasodilator stress magnetic resonance perfusion study. <i>Journal of Clinical Lipidology</i> , 2016, 10, 314-322.	1.5	4
89	Advances in diagnosis and potential therapeutic options for familial chylomicronemia syndrome. <i>Expert Opinion on Orphan Drugs</i> , 2018, 6, 141-149.	0.8	4
90	Left ventricular mass regression, all-cause and cardiovascular mortality in chronic kidney disease: a meta-analysis. <i>BMC Nephrology</i> , 2022, 23, 34.	1.8	4

#	ARTICLE	IF	CITATIONS
91	Overview of prevention and treatment of atherosclerosis with lipid-altering therapy for pharmacy directors. <i>American Journal of Managed Care</i> , 2007, 13 Suppl 10, S260-9.	1.1	4
92	Introduction. <i>American Journal of Cardiology</i> , 2008, 101, S1-S2.	1.6	3
93	Introduction. <i>American Journal of Cardiology</i> , 2008, 101, S1-S2.	1.6	3
94	Medical management of patients before the incidence of a cardiovascular event. <i>Journal of Clinical Lipidology</i> , 2009, 3, 315-321.	1.5	3
95	Changing characteristics of statin-related cIMT trials from 1988 to 2006. <i>Atherosclerosis</i> , 2016, 246, 121-129.	0.8	3
96	Recent advances and emerging therapies in management of dyslipidemias. <i>Trends in Cardiovascular Medicine</i> , 2021, 31, 419-424.	4.9	3
97	Omega-3 fatty acid exposure with a low-fat diet in patients with past hypertriglyceridemia-induced acute pancreatitis; an exploratory, randomized, open-label crossover study. <i>Lipids in Health and Disease</i> , 2020, 19, 117.	3.0	3
98	Introduction. <i>American Journal of Cardiology</i> , 2009, 104, 1E-2E.	1.6	2
99	Beta-2 Agonism: A Potential Therapeutic Target for Dyslipidemia. <i>EBioMedicine</i> , 2015, 2, 284.	6.1	2
100	Update on PCSK9 therapies for the treatment of dyslipidemia. <i>Expert Review of Endocrinology and Metabolism</i> , 2016, 11, 87-95.	2.4	2
101	Assessment of pharmacokinetic interaction between omega-3 carboxylic acids and the statins rosuvastatin and simvastatin: Results of 2 phase I studies in healthy volunteers. <i>Journal of Clinical Lipidology</i> , 2017, 11, 739-748.	1.5	2
102	Use of microsomal triglyceride transfer protein inhibitors in patients with homozygous familial hypercholesterolemia: translating clinical trial experience into clinical practice. <i>Reviews in Cardiovascular Medicine</i> , 2014, 15, 1-10.	1.4	2
103	Combination Therapy with Statins. <i>Endocrinology and Metabolism Clinics of North America</i> , 2014, 43, 993-1006.	3.2	1
104	Using Discordance in Monozygotic Twins to Understand Causality of Cardiovascular Disease Risk Factors. <i>JAMA Internal Medicine</i> , 2016, 176, 1530.	5.1	1
105	Intensive statin therapy in India: Demonstrating efficacy and safety. <i>Indian Heart Journal</i> , 2016, 68, 756-757.	0.5	1
106	Time-related trends in variability of cIMT changes in statin trials. <i>Data in Brief</i> , 2016, 6, 530-541.	1.0	1
107	No Effect of Omega-3 Carboxylic Acids on Pharmacokinetics/Pharmacodynamics of Warfarin or on Platelet Function When Co-administered with Acetylsalicylic Acid: Results of Two Phase I Studies in Healthy Volunteers. <i>American Journal of Cardiovascular Drugs</i> , 2017, 17, 251-260.	2.2	1
108	The Role of Genetics in Cardiovascular Risk Reduction: Findings From a Single Lipid Clinic and Review of the Literature. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 200-204.	0.8	1

#	ARTICLE	IF	CITATIONS
109	Reducing cardiovascular risk: trends in risk, risk assessment, and cholesterol management. Postgraduate Medicine, 2004, 116, 7-12.	2.0	1
110	Counterpoint: Low-density lipoprotein cholesterol goals in patients with diabetes are adequately based on evidence. Journal of Clinical Lipidology, 2010, 4, 72-73.	1.5	0
111	Introduction. American Journal of Cardiology, 2012, 110, 1B-3B.	1.6	0